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Therapeutic peptides offer significant opportunities to treat serious and debilitating diseases, with several 
purported advantages over proteins, such as a simpler characterization process and a reduced regulatory 
burden. However, many peptides are known to be susceptible to aggregation, and surprisingly little work has 
been published on designing formulation principles for these therapeutic agents. 
 
In this paper the focus will be on the challenges encountered in rational development of a stabilization strategy 
for two model peptides formulated at high concentration (>50 mg/ml). The first model peptide studied was 
carbetocin, a 9-amino acid long analogue of oxytocin with improved chemical and enzymatic stability. At high 
concentrations (70 mg/mL, ca 70 mM) carbetocin is sensitive to interface-induced stress, causing the formation 
of large amorphous aggregates. The addition of uncharged or charged surfactants surprisingly did not stabilize 
against this interface-induced stress; instead, positively and negatively charged surfactants steered the 
aggregation pathway towards the formation of amyloid-like fibrils [1]. The addition of very low concentrations of 
the uncharged surfactant Span 60 appeared to result in the formation of aggregates with a refractive index close 
to that of water, creating a false impression of stabilization. For carbetocin, only the removal of the air-water 
interface by fully filling the vials resulted in a significant stabilization against aggregation [1]. 
 
The second model peptide was a 33-amino acid negatively charged peptide which formed amyloid-like fibrils 
when exposed to heat stress (40 degrees C) at 50 mg/mL concentration. The limited impact of shaking indicated 
this fibrillation was primarily induced through peptide-peptide interactions in the bulk solution. Peptide-peptide 
interactions were therefore determined using Taylor Dispersion Analysis. The latter method suggested 
significant repulsive interactions for this peptide formulation in aqueous solution. Addition of salt (NaCl) or the 
amino acids Arg or Glu at 150 mM shielded these repulsive interactions. In contrast, addition of 250 mM of the 
amino acids Val or Ile had a very limited shielding effect. However, none of the added excipients appeared to 
stabilize the peptide against aggregation, although infrared spectroscopic analysis indicated that the aggregates 
in the NaCl, Arg and Glu containing solutions consisted of native-like peptides. The aggregates formed in the 
presence of Val and Ile, or in the absence of any excipients, contained a significant amount of intermolecular 
beta-sheet [2]. 
 
Our results illustrate the challenges in protecting high concentration peptides against aggregation and indicates 
a strong dependence of the aggregation pathway on the excipients added and their potential interaction with the 
peptide. A novel formulation toolbox may therefore be required for peptides. The high structural flexibility 
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